DRC Begins Trial of Experimental Ebola Treatments as Outbreak Spreads

Health authorities in the Democratic Republic of Congo launched a clinical trial of two experimental Ebola treatments on Thursday as the outbreak that began on 15 May continues to spread in the north-east of the country. The study is evaluating the monoclonal antibody MBP134 and the antiviral drug remdesivir, administered separately and in combination, against the Bundibugyo strain of Ebola.

No approved vaccines or specific treatments exist for this strain.

Officials have recorded 1,460 confirmed cases and 447 deaths since the outbreak was declared, producing a fatality rate of 30.6 percent. The outbreak remains centered in Ituri province, where most deaths have occurred. Cases have also been reported in North Kivu and South Kivu.

A first infection has been confirmed in Kisangani, a major city distant from the original epicenter. The case in Kisangani involved a 24-year-old pregnant woman whose body was transported by motorcycle from Nia Nia in Ituri, highlighting risks from unsafe handling of the deceased.

The World Health Organization said the first patient has been enrolled in the trial. Director-general Tedros Adhanom Ghebreyesus stated the study could last several months and may involve more than 1,000 patients. Participants will receive supportive care and close monitoring.

The agency is also working to secure post-trial access to the drugs if they prove safe and effective. An average of 38 new confirmed cases per day have been recorded over the past two weeks. Health workers in Ituri have faced resistance from some communities.